O	0	10	Inhibition	Inhibition	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	17	the	the	DT	B-NP
O	18	27	mammalian	mammalian	JJ	I-NP
O	28	34	target	target	NN	I-NP
O	35	37	of	of	IN	B-PP
O	38	47	rapamycin	rapamycin	NN	B-NP
O	48	49	(	(	(	O
O	49	53	mTOR	mTOR	NN	B-NP
O	53	54	)	)	)	O
O	55	57	by	by	IN	B-PP
O	58	67	rapamycin	rapamycin	NN	B-NP
O	68	77	increases	increase	VBZ	B-VP
O	78	94	chemosensitivity	chemosensitivity	NN	B-NP
O	95	97	of	of	IN	B-PP
B-Cell	98	103	CaSki	CaSki	NNP	B-NP
I-Cell	104	109	cells	cell	NNS	I-NP
O	110	112	to	to	TO	B-PP
O	113	123	paclitaxel	paclitaxel	NN	B-NP
O	123	124	.	.	.	O

O	126	136	Paclitaxel	Paclitaxel	NNP	B-NP
O	136	137	,	,	,	O
O	138	139	a	a	DT	B-NP
O	140	146	potent	potent	JJ	I-NP
O	147	151	anti	anti	AFX	I-NP
O	151	152	-	-	HYPH	I-NP
B-Cancer	152	162	neoplastic	neoplastic	JJ	I-NP
O	163	168	agent	agent	NN	I-NP
O	168	169	,	,	,	O
O	170	173	has	have	VBZ	B-VP
O	174	178	been	be	VBN	I-VP
O	179	184	found	find	VBN	I-VP
O	185	187	to	to	TO	I-VP
O	188	190	be	be	VB	I-VP
O	191	200	effective	effective	JJ	B-ADJP
O	201	208	against	against	IN	B-PP
O	209	216	several	several	JJ	B-NP
B-Cancer	217	224	tumours	tumour	NNS	I-NP
O	224	225	,	,	,	O
O	226	235	including	include	VBG	B-PP
B-Cancer	236	244	cervical	cervical	JJ	B-NP
I-Cancer	245	251	cancer	cancer	NN	I-NP
O	251	252	.	.	.	O

O	253	260	However	However	RB	B-ADVP
O	260	261	,	,	,	O
O	262	265	the	the	DT	B-NP
O	266	271	exact	exact	JJ	I-NP
O	272	281	mechanism	mechanism	NN	I-NP
O	282	292	underlying	underlie	VBG	B-VP
O	293	296	the	the	DT	B-NP
O	297	306	cytotoxic	cytotoxic	JJ	I-NP
O	307	314	effects	effect	NNS	I-NP
O	315	317	of	of	IN	B-PP
O	318	327	pacitaxel	pacitaxel	NN	B-NP
O	327	328	,	,	,	O
O	329	339	especially	especially	RB	B-ADVP
O	340	342	in	in	IN	B-PP
O	343	346	the	the	DT	B-NP
O	347	355	survival	survival	NN	I-NP
O	355	356	-	-	HYPH	B-NP
O	356	366	signalling	signalling	NN	I-NP
O	367	374	pathway	pathway	NN	I-NP
O	374	375	,	,	,	O
O	376	378	is	be	VBZ	B-VP
O	379	385	poorly	poorly	RB	B-ADJP
O	386	396	understood	understand	VBN	I-ADJP
O	396	397	.	.	.	O

O	398	401	The	The	DT	B-NP
O	402	405	aim	aim	NN	I-NP
O	406	408	of	of	IN	B-PP
O	409	413	this	this	DT	B-NP
O	414	419	study	study	NN	I-NP
O	420	423	was	be	VBD	B-VP
O	424	426	to	to	TO	B-VP
O	427	438	investigate	investigate	VB	I-VP
O	439	442	the	the	DT	B-NP
O	443	452	molecular	molecular	JJ	I-NP
O	453	460	pathway	pathway	NN	I-NP
O	461	463	of	of	IN	B-PP
O	464	467	the	the	DT	B-NP
O	468	477	cytotoxic	cytotoxic	JJ	I-NP
O	478	484	effect	effect	NN	I-NP
O	485	487	of	of	IN	B-PP
O	488	498	paclitaxel	paclitaxel	NN	B-NP
O	499	501	in	in	IN	B-PP
O	502	507	human	human	JJ	B-NP
B-Cell	508	516	cervical	cervical	JJ	I-NP
I-Cell	517	523	cancer	cancer	NN	I-NP
I-Cell	524	528	cell	cell	NN	I-NP
I-Cell	529	534	lines	line	NNS	I-NP
O	534	535	.	.	.	O

O	536	540	Four	Four	CD	B-NP
O	541	546	human	human	JJ	I-NP
B-Cell	547	555	cervical	cervical	JJ	I-NP
I-Cell	556	562	cancer	cancer	NN	I-NP
I-Cell	563	567	cell	cell	NN	I-NP
I-Cell	568	573	lines	line	NNS	I-NP
O	574	578	were	be	VBD	B-VP
O	579	586	treated	treat	VBN	I-VP
O	587	590	for	for	IN	B-PP
O	591	593	24	24	CD	B-NP
O	594	595	h	h	NN	I-NP
O	596	600	with	with	IN	B-PP
O	601	608	various	various	JJ	B-NP
O	609	622	concentration	concentration	NN	I-NP
O	623	625	of	of	IN	B-PP
O	626	636	paclitaxel	paclitaxel	NN	B-NP
O	636	637	,	,	,	O
O	638	641	and	and	CC	O
O	642	645	the	the	DT	B-NP
O	646	657	sensitivity	sensitivity	NN	I-NP
O	658	661	was	be	VBD	B-VP
O	662	670	analysed	analyse	VBN	I-VP
O	671	673	by	by	IN	B-PP
O	674	676	an	an	DT	B-NP
O	677	680	MTT	MTT	NN	I-NP
O	681	686	assay	assay	NN	I-NP
O	686	687	.	.	.	O

O	688	691	The	The	DT	B-NP
B-Cell	692	696	cell	cell	NN	I-NP
O	697	702	cycle	cycle	NN	I-NP
O	703	714	progression	progression	NN	I-NP
O	715	718	and	and	CC	O
O	719	722	sub	sub	AFX	B-NP
O	722	723	-	-	HYPH	I-NP
O	723	725	G1	G1	NN	I-NP
O	726	736	population	population	NN	I-NP
O	737	741	were	be	VBD	B-VP
O	742	750	analysed	analyse	VBN	I-VP
O	751	753	by	by	IN	B-PP
O	754	758	flow	flow	NN	B-NP
O	759	768	cytometry	cytometry	NN	I-NP
O	768	769	.	.	.	O

O	770	779	Apoptosis	Apoptosis	NN	B-NP
O	780	783	was	be	VBD	B-VP
O	784	791	further	further	RBR	I-VP
O	792	800	measured	measure	VBN	I-VP
O	801	803	by	by	IN	B-PP
O	804	807	DNA	DNA	NN	B-NP
O	808	821	fragmentation	fragmentation	NN	I-NP
O	822	825	and	and	CC	I-NP
O	826	836	microscope	microscope	NN	I-NP
O	837	848	examination	examination	NN	I-NP
O	848	849	.	.	.	O

O	850	853	The	The	DT	B-NP
O	854	861	protein	protein	NN	I-NP
O	862	872	expression	expression	NN	I-NP
O	873	876	was	be	VBD	B-VP
O	877	887	determined	determine	VBN	I-VP
O	888	890	by	by	IN	B-PP
O	891	898	Western	Western	JJ	B-NP
O	899	903	blot	blot	NN	I-NP
O	904	912	analysis	analysis	NN	I-NP
O	912	913	.	.	.	O

O	914	917	Our	Our	PRP$	B-NP
O	918	925	results	result	NNS	I-NP
O	926	932	showed	show	VBD	B-VP
O	933	937	that	that	IN	B-SBAR
B-Cell	938	942	HeLa	HeLa	NN	B-NP
I-Cell	943	948	cells	cell	NNS	I-NP
O	949	961	demonstrated	demonstrate	VBD	B-VP
O	962	965	the	the	DT	B-NP
O	966	973	highest	high	JJS	I-NP
O	974	985	sensitivity	sensitivity	NN	I-NP
O	986	988	to	to	TO	B-PP
O	989	999	paclitaxel	paclitaxel	NN	B-NP
O	999	1000	,	,	,	O
O	1001	1008	whereas	whereas	IN	O
B-Cell	1009	1014	CaSki	CaSki	NN	B-NP
I-Cell	1015	1020	cells	cell	NNS	I-NP
O	1021	1027	showed	show	VBD	B-VP
O	1028	1031	the	the	DT	B-NP
O	1032	1038	lowest	low	JJS	I-NP
O	1038	1039	.	.	.	O

O	1040	1042	In	In	IN	B-PP
B-Cell	1043	1051	cervical	cervical	JJ	B-NP
I-Cell	1052	1058	cancer	cancer	NN	I-NP
I-Cell	1059	1064	cells	cell	NNS	I-NP
O	1064	1065	,	,	,	O
O	1066	1076	paclitaxel	paclitaxel	NN	B-NP
O	1077	1084	induced	induce	VBD	B-VP
O	1085	1094	apoptosis	apoptosis	NN	B-NP
O	1095	1102	through	through	IN	B-PP
O	1103	1105	an	an	DT	B-NP
O	1106	1115	intrinsic	intrinsic	JJ	I-NP
O	1116	1123	pathway	pathway	NN	I-NP
O	1124	1128	with	with	IN	B-PP
O	1129	1134	prior	prior	JJ	B-NP
O	1135	1137	G2	G2	NN	I-NP
O	1137	1138	/	/	SYM	B-VP
O	1138	1139	M	M	NN	B-NP
O	1140	1146	arrest	arrest	NN	I-NP
O	1146	1147	.	.	.	O

O	1148	1150	In	In	IN	B-PP
O	1151	1159	addition	addition	NN	B-NP
O	1159	1160	,	,	,	O
O	1161	1163	we	we	PRP	B-NP
O	1164	1170	showed	show	VBD	B-VP
O	1171	1175	that	that	IN	B-SBAR
O	1176	1186	paclitaxel	paclitaxel	NN	B-NP
O	1187	1200	downregulated	downregulate	VBD	B-VP
O	1201	1204	the	the	DT	B-NP
O	1205	1220	phosphorylation	phosphorylation	NN	I-NP
O	1221	1223	of	of	IN	B-PP
O	1224	1227	Akt	Akt	NN	B-NP
O	1228	1230	in	in	IN	B-PP
O	1231	1235	both	both	CC	O
B-Cell	1236	1240	HeLa	HeLa	NN	B-NP
O	1241	1244	and	and	CC	O
B-Cell	1245	1250	CaSki	CaSki	NN	B-NP
I-Cell	1251	1256	cells	cell	NNS	I-NP
O	1256	1257	.	.	.	O

O	1258	1271	Interestingly	Interestingly	RB	B-ADVP
O	1271	1272	,	,	,	O
O	1273	1275	in	in	IN	B-PP
B-Cell	1276	1281	CaSki	CaSki	NNP	B-NP
I-Cell	1282	1287	cells	cell	NNS	I-NP
O	1287	1288	,	,	,	O
O	1289	1294	which	which	WDT	B-NP
O	1295	1299	were	be	VBD	B-VP
O	1300	1304	more	more	RBR	B-ADJP
O	1305	1315	suggestive	suggestive	JJ	I-ADJP
O	1316	1318	of	of	IN	B-PP
O	1319	1320	a	a	DT	B-NP
O	1321	1330	resistant	resistant	JJ	I-NP
O	1331	1340	phenotype	phenotype	NN	I-NP
O	1340	1341	,	,	,	O
O	1342	1352	paclitaxel	paclitaxel	NN	B-NP
O	1353	1360	induced	induce	VBD	B-VP
O	1361	1364	the	the	DT	B-NP
O	1365	1375	activation	activation	NN	I-NP
O	1376	1378	of	of	IN	B-PP
O	1379	1383	mTOR	mTOR	NN	B-NP
O	1384	1386	as	as	IN	B-PP
O	1387	1388	a	a	DT	B-NP
O	1389	1399	downstream	downstream	JJ	I-NP
O	1400	1406	target	target	NN	I-NP
O	1407	1409	of	of	IN	B-PP
O	1410	1413	Akt	Akt	NN	B-NP
O	1413	1414	.	.	.	O

O	1415	1418	Pre	Pre	AFX	B-NP
O	1418	1419	-	-	HYPH	I-NP
O	1419	1428	treatment	treatment	NN	B-NP
O	1429	1433	with	with	IN	B-PP
O	1434	1443	rapamycin	rapamycin	NN	B-NP
O	1444	1453	inhibited	inhibit	VBD	B-VP
O	1454	1464	activation	activation	NN	B-NP
O	1465	1467	of	of	IN	B-PP
O	1468	1472	mTOR	mTOR	NN	B-NP
O	1473	1483	signalling	signalling	NN	I-NP
O	1484	1487	and	and	CC	O
O	1488	1501	significantly	significantly	RB	B-VP
O	1502	1510	enhanced	enhance	VBD	I-VP
O	1511	1514	the	the	DT	B-NP
O	1515	1526	sensitivity	sensitivity	NN	I-NP
O	1527	1529	of	of	IN	B-PP
B-Cell	1530	1535	CaSki	CaSki	NNP	B-NP
I-Cell	1536	1541	cells	cell	NNS	I-NP
O	1542	1544	to	to	TO	B-PP
O	1545	1555	paclitaxel	paclitaxel	NN	B-NP
O	1556	1558	by	by	IN	B-PP
O	1559	1569	increasing	increase	VBG	B-VP
O	1570	1579	apoptotic	apoptotic	JJ	B-NP
B-Cell	1580	1584	cell	cell	NN	I-NP
O	1585	1590	death	death	NN	I-NP
O	1590	1591	.	.	.	O

O	1592	1596	This	This	DT	B-NP
O	1597	1603	effect	effect	NN	I-NP
O	1604	1607	was	be	VBD	B-VP
O	1608	1616	mediated	mediate	VBN	I-VP
O	1616	1617	,	,	,	O
O	1618	1620	at	at	IN	B-ADVP
O	1621	1626	least	least	JJS	I-ADVP
O	1627	1633	partly	partly	RB	B-ADVP
O	1633	1634	,	,	,	O
O	1635	1642	through	through	IN	B-PP
O	1643	1650	caspase	caspase	NN	B-NP
O	1651	1661	activation	activation	NN	I-NP
O	1661	1662	.	.	.	O

O	1663	1670	Overall	Overall	RB	B-ADVP
O	1670	1671	,	,	,	O
O	1672	1682	paclitaxel	paclitaxel	NN	B-NP
O	1683	1689	exerts	exert	VBZ	B-VP
O	1690	1693	its	its	PRP$	B-NP
O	1694	1698	anti	anti	AFX	I-NP
O	1698	1699	-	-	HYPH	I-NP
B-Cancer	1699	1705	tumour	tumour	NN	I-NP
O	1706	1713	effects	effect	NNS	I-NP
O	1714	1716	on	on	IN	B-PP
B-Cell	1717	1725	cervical	cervical	JJ	B-NP
I-Cell	1726	1732	cancer	cancer	NN	I-NP
I-Cell	1733	1738	cells	cell	NNS	I-NP
O	1739	1741	by	by	IN	B-PP
O	1742	1750	inducing	induce	VBG	B-VP
O	1751	1760	apoptosis	apoptosis	NN	B-NP
O	1761	1768	through	through	IN	B-PP
O	1769	1778	intrinsic	intrinsic	JJ	B-NP
O	1779	1786	pathway	pathway	NN	I-NP
O	1786	1787	,	,	,	O
O	1788	1791	and	and	CC	O
O	1792	1801	rapamycin	rapamycin	NN	B-NP
O	1802	1810	targeted	target	VBN	B-VP
O	1811	1813	to	to	TO	B-PP
O	1814	1818	mTOR	mTOR	NN	B-NP
O	1819	1822	can	can	MD	B-VP
O	1823	1832	sensitise	sensitise	VB	I-VP
O	1833	1843	paclitaxel	paclitaxel	NN	B-NP
O	1843	1844	-	-	HYPH	O
O	1844	1853	resistant	resistant	JJ	B-NP
B-Cell	1854	1862	cervical	cervical	JJ	I-NP
I-Cell	1863	1869	cancer	cancer	NN	I-NP
I-Cell	1870	1875	cells	cell	NNS	I-NP
O	1875	1876	.	.	.	O

